3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
2
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Multiple Myeloma
1
Lymphoma, Non-Hodgkin
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Interventions
Cyclophosphamide
172
Rituximab
161
Specimen Handling
115
Biopsy
92
Magnetic Resonance Spectroscopy
90
Vincristine
88
Doxorubicin
82
Prednisone
80
fludarabine
71
venetoclax
70
obinutuzumab
63
Lenalidomide
56
ibrutinib
55
Dexamethasone
55
Cytarabine
49
Methotrexate
47
acalabrutinib
43
Etoposide
43
CT-P10
41
blinatumomab
38
fludarabine phosphate
35
Bendamustine Hydrochloride
35
Gemcitabine
33
prednylidene
32
zanubrutinib
31
deltacortene
31
pembrolizumab
30
Calcium Dobesilate
30
glofitamab
29
Nivolumab
27
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Hizentra
×
Lymphoid
×
90 days
×
Clear all
NCT07582432
2026-05-12
SIGMA
Grifols Biologicals, LLC
Phase 3
Recruiting
49 enrolled